{"id":12238,"date":"2018-12-19T07:59:57","date_gmt":"2018-12-19T12:59:57","guid":{"rendered":"https:\/\/medicarereport.org\/?p=12238"},"modified":"2018-12-19T07:59:57","modified_gmt":"2018-12-19T12:59:57","slug":"powerful-democrat-wants-pfizer-to-explain-price-hikes-for-lyrica-its-nerve-pain-drug","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=12238","title":{"rendered":"Powerful Democrat wants Pfizer to explain price hikes for Lyrica, its nerve pain drug"},"content":{"rendered":"<p>(By Nicholas Florko for ST<em>A<\/em>T)<\/p>\n<p><span class=\"big-cap-wrap\"><span class=\"big-cap\">W<\/span><\/span>ASHINGTON \u2014 A powerful Senate Democrat is asking Pfizer to explain why it hiked the price of its nerve pain drug, Lyrica. And if Sen. Ron Wyden (D-Ore.) has his way, more companies will soon be asked to account for their decisions to raise prices.\u00a0 <a href=\"https:\/\/www.statnews.com\/2018\/12\/19\/wyden-pfizer-lyrica-hikes\/?utm_campaign=KHN%3A%20First%20Edition&amp;utm_source=hs_email&amp;utm_medium=email&amp;utm_content=68456347&amp;_hsenc=p2ANqtz-9gEd0ZioRzf8L8f8tOa8hKq8Cg33rXVFUnK6a3nm7EaxmwlCCDZOOULDnITiuupWQIN6h4VVRbW8ntEyklrjDTqdy14w&amp;_hsmi=68456347\">Continue reading article here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<pre>Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Nicholas Florko for STAT) WASHINGTON \u2014 A powerful Senate Democrat is asking Pfizer to explain why it hiked the<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10,15],"tags":[],"class_list":["post-12238","post","type-post","status-publish","format-standard","hentry","category-legislative-update","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/12238","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12238"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/12238\/revisions"}],"predecessor-version":[{"id":12239,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/12238\/revisions\/12239"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12238"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12238"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12238"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}